A rapid point of care test for qualitative assessment of neutralizing antibodies to SARS-CoV-2 (virus responsible for COVID-19) in human blood, plasma, and serum. Currently available for research use only.
Highly sensitive and specific.
CoNAb is a competitive assay that utilizes colloidal gold conjugated S1-protein of SARS-CoV-2 to bind to the ACE2 molecule coated on the test strip. SARS-CoV-2 neutralizing antibody (NAb) will bind to the S1-protein and inhibit its binding to ACE2.
Intended Use: The test is intended for laboratory use to qualitatively measure the level of SARS-CoV-2 NAb in whole blood, plasma, serum or fingertip blood from individuals who have completed a COVID-19 vaccination process or were previously infected by SARS-CoV-2. CoNAb is limited for Research Use Only before being authorized by FDA or CE Mark for diagnostic use
